ARCHIVES

ASCO: NCI Authorities Still Important

This article is from The Cancer Letter archive.

Vol. 36 No. 22 | June 11, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Freireich’s Seven Laws To Protect Against Obstacles To Clinical Research

May 14, 1976

In Brief: Scientist Bands Entertain Writers

December 19, 1997

Medenica’s Claims Of Association On CV, Brochures, Challenged By Some Institutions

April 30, 1993

In Brief: McDonough Leaves Komen Foundation; Henderson To Head Salk Institute; Alabama Recruits Two

December 4, 1992